Synthego Welcomes Supreme Court Ruling Finalizing Invalidation of Agilent CRISPR Patents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy A?
Source: Yahoo Finance
- Legal Challenge Concluded: The U.S. Supreme Court denied Agilent Technologies' petition, effectively concluding a multi-year legal battle and solidifying the invalidation of two CRISPR-related patents, thereby removing significant legal barriers to gene editing technologies.
- Patent Invalidation Affirmed: The Supreme Court's decision upholds the June 2025 ruling by the U.S. Court of Appeals, confirming that Agilent's patents (Nos. 10,337,001 and 10,900,034) are unpatentable, fostering a more open environment for scientific innovation.
- Innovation Promotion: Synthego's CEO Craig Christianson emphasized that this ruling is not just about resolving a single dispute but reflects a commitment to the scientific community, aiming to clear patent obstacles in gene editing to enhance innovation for researchers and therapeutic developers.
- New Product Development: With the patents invalidated, Synthego plans to introduce novel nucleases and CRISPR technologies, further solidifying its leadership in the cell and gene therapy space and accelerating scientific discovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 121.870
Low
160.00
Averages
171.67
High
180.00
Current: 121.870
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Synthego Welcomes Supreme Court Ruling Finalizing Invalidation of Agilent CRISPR Patents
- Legal Challenge Concluded: The U.S. Supreme Court denied Agilent Technologies' petition, effectively concluding a multi-year legal battle and solidifying the invalidation of two CRISPR-related patents, thereby removing significant legal barriers to gene editing technologies.
- Patent Invalidation Affirmed: The Supreme Court's decision upholds the June 2025 ruling by the U.S. Court of Appeals, confirming that Agilent's patents (Nos. 10,337,001 and 10,900,034) are unpatentable, fostering a more open environment for scientific innovation.
- Innovation Promotion: Synthego's CEO Craig Christianson emphasized that this ruling is not just about resolving a single dispute but reflects a commitment to the scientific community, aiming to clear patent obstacles in gene editing to enhance innovation for researchers and therapeutic developers.
- New Product Development: With the patents invalidated, Synthego plans to introduce novel nucleases and CRISPR technologies, further solidifying its leadership in the cell and gene therapy space and accelerating scientific discovery.
See More
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval for New Indication: Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) has received FDA approval as a companion diagnostic to help identify patients with esophageal or gastroesophageal junction carcinoma eligible for Merck's KEYTRUDA treatment, further solidifying its position in precision medicine.
- Eighth Indication: This approval marks the eighth FDA-approved indication for PD-L1 IHC 22C3 pharmDx, showcasing the product's broad application potential in cancer treatment, which may drive Agilent's growth in the clinical diagnostics market.
- Positive Market Reaction: In pre-market trading on the NYSE, Agilent shares rose by 0.46% to $113.48, reflecting investor confidence in the company's newly approved product and optimistic expectations for its future market performance.
- Supporting Clinical Decisions: Nina Green, Vice President and General Manager of Agilent's Clinical Diagnostics Division, stated that the expanded FDA approval of PD-L1 IHC 22C3 pharmDx will assist clinicians in better identifying patients suitable for KEYTRUDA treatment, thereby enhancing treatment efficacy and patient survival rates.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval: Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic tool aimed at identifying patients with esophageal or gastroesophageal junction carcinoma eligible for KEYTRUDA treatment, marking a significant advancement in the field of precision medicine.
- Market Demand Response: This diagnostic tool is specifically designed to identify patients with PD-L1 expression ≥ 1, which is expected to significantly enhance treatment options for esophageal cancer patients, addressing the urgent market demand for precision therapies and reinforcing Agilent's leadership in the cancer diagnostics market.
- Multiple Indications: In addition to esophageal cancer, PD-L1 IHC 22C3 pharmDx is also indicated for identifying patients with non-small cell lung cancer, cervical cancer, and other cancers, thereby broadening its market application and enhancing Agilent's product competitiveness.
- Strong Financial Performance: Agilent reported revenues of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people; with the launch of this new diagnostic tool, future revenue growth is anticipated, solidifying its position in the global clinical diagnostics market.
See More
Crawford & Company Appoints New CEO
- New CEO Appointment: Crawford & Company has appointed W. Bruce Swain Jr. as President and CEO effective immediately, having served in an interim capacity since January 1, which reflects the company's confidence in his leadership capabilities.
- Board Changes: Board member Jesse C. Crawford Sr. announced he will not seek re-election at the 2026 annual shareholder meeting, marking the end of over four decades with the firm, indicating a significant shift in the company's governance structure.
- Honorary Title Bestowal: Following the shareholder meeting, Crawford Sr. will be named an honorary board member and emeritus officer, recognizing his long-term contributions while facilitating a smooth transition to the new board.
- Future Outlook: The company anticipates a subdued claims environment in Q1 2026, reflecting current market challenges and uncertainties that may impact overall performance, highlighting the need for strategic adjustments moving forward.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Synthego Welcomes Supreme Court Ruling Finalizing Invalidation of Agilent CRISPR Patents
- Legal Challenge Concluded: The U.S. Supreme Court denied Agilent Technologies' petition, effectively concluding a multi-year legal battle and solidifying the invalidation of two CRISPR-related patents, thereby removing significant legal barriers to gene editing technologies.
- Patent Invalidation Affirmed: The Supreme Court's decision upholds the June 2025 ruling by the U.S. Court of Appeals, confirming that Agilent's patents (Nos. 10,337,001 and 10,900,034) are unpatentable, fostering a more open environment for scientific innovation.
- Innovation Promotion: Synthego's CEO Craig Christianson emphasized that this ruling is not just about resolving a single dispute but reflects a commitment to the scientific community, aiming to clear patent obstacles in gene editing to enhance innovation for researchers and therapeutic developers.
- New Product Development: With the patents invalidated, Synthego plans to introduce novel nucleases and CRISPR technologies, further solidifying its leadership in the cell and gene therapy space and accelerating scientific discovery.
See More
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval for New Indication: Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) has received FDA approval as a companion diagnostic to help identify patients with esophageal or gastroesophageal junction carcinoma eligible for Merck's KEYTRUDA treatment, further solidifying its position in precision medicine.
- Eighth Indication: This approval marks the eighth FDA-approved indication for PD-L1 IHC 22C3 pharmDx, showcasing the product's broad application potential in cancer treatment, which may drive Agilent's growth in the clinical diagnostics market.
- Positive Market Reaction: In pre-market trading on the NYSE, Agilent shares rose by 0.46% to $113.48, reflecting investor confidence in the company's newly approved product and optimistic expectations for its future market performance.
- Supporting Clinical Decisions: Nina Green, Vice President and General Manager of Agilent's Clinical Diagnostics Division, stated that the expanded FDA approval of PD-L1 IHC 22C3 pharmDx will assist clinicians in better identifying patients suitable for KEYTRUDA treatment, thereby enhancing treatment efficacy and patient survival rates.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval: Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic tool aimed at identifying patients with esophageal or gastroesophageal junction carcinoma eligible for KEYTRUDA treatment, marking a significant advancement in the field of precision medicine.
- Market Demand Response: This diagnostic tool is specifically designed to identify patients with PD-L1 expression ≥ 1, which is expected to significantly enhance treatment options for esophageal cancer patients, addressing the urgent market demand for precision therapies and reinforcing Agilent's leadership in the cancer diagnostics market.
- Multiple Indications: In addition to esophageal cancer, PD-L1 IHC 22C3 pharmDx is also indicated for identifying patients with non-small cell lung cancer, cervical cancer, and other cancers, thereby broadening its market application and enhancing Agilent's product competitiveness.
- Strong Financial Performance: Agilent reported revenues of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people; with the launch of this new diagnostic tool, future revenue growth is anticipated, solidifying its position in the global clinical diagnostics market.
See More
Crawford & Company Appoints New CEO
- New CEO Appointment: Crawford & Company has appointed W. Bruce Swain Jr. as President and CEO effective immediately, having served in an interim capacity since January 1, which reflects the company's confidence in his leadership capabilities.
- Board Changes: Board member Jesse C. Crawford Sr. announced he will not seek re-election at the 2026 annual shareholder meeting, marking the end of over four decades with the firm, indicating a significant shift in the company's governance structure.
- Honorary Title Bestowal: Following the shareholder meeting, Crawford Sr. will be named an honorary board member and emeritus officer, recognizing his long-term contributions while facilitating a smooth transition to the new board.
- Future Outlook: The company anticipates a subdued claims environment in Q1 2026, reflecting current market challenges and uncertainties that may impact overall performance, highlighting the need for strategic adjustments moving forward.
See More
